Auriga Partners

Vade Secure is the global leader on anti-phishing, spear phishing, malware and ransomware with heuristic filtering. Language independent, the filter analyzes globally all incoming emails (links, attached files, content…) to detect all threats in zero-day, even the most targeted attacks. After elimination all threats, we eliminate the nuisance of low priority emails with the Graymail Management. Ads, social networks notifications, and newsletters are automatically sent to the graymail folder while the Safe Unsubscribe button eliminate them forever. Protecting more than 500 million of mailboxes in 76 countries, our solutions are used by major ISPs, OEMs, and Enterprises worldwide. Vade Secure is implanted in 5 countries (USA, Canada, France, Hong Kong, and Japan) to offer a 24/7 support. For more information, please visit www.vadesecure.com/en.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.

EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet, electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios. The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample to improve the performance of urinary cytology conventionally used in first intention.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Senders™ is a contextual intelligence email service offered by One More Company, Inc, the company behind Trackbuster™, which offered the same email untracking features now available as part of Senders. Senders is the latest product from One More Company. It functions like Caller ID for email by providing the recipient more information about the sender right in the email, so it works everywhere, regardless of app, platform, and device. Senders™ is a patent-pending service designed and securely hosted in the US. They are focused on enhancing the email experience for individuals and businesses by helping users filter the messaging signal from the noise and providing relevant information on the fly, in an open way. They provide simple, intuitive services around messaging and the cloud. They are driven by a digital ethics based on consumer control, privacy, and transparency. Their users are their customers and their interests are paramount. Their business model is not based on selling ads, or collecting and selling data. At One More Company, Inc., creating a positive consumer experience is their highest priority, and their raison d’être. Their products are designed to make life easier. They can’t do that without ensuring user privacy and the security of personal information. So, they think about privacy and security from the beginning, and throughout the product design process; in other words, privacy by design. One More Company, Inc is a U.S. corporation founded by seasoned executives with decades of experience in Silicon Valley, at places like Google, Facebook, Twitter, and IBM. It has offices in New York and Paris. Senders™ is a patent-pending service designed and securely hosted in the USA.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet, electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios. The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.

Theranexus is a clinical-stage pharmaceutical company that aims to develop technology to address severe medical needs in brain disorders. The company is based in France.

aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet, electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios. The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Amoeba is focused on developing and commercializing green biocide water treatment chemicals. It offers BIOMEBA, a green biocide that harnesses the biocidal properties of Willaertia magna to treat the bacterial risks encountered in cooling towers.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

Founded in 2009 in Lyon, France and located and member of LyonBiopôle cluster, Fab’entech is a biopharmaceutical company which develops and commercializes a range of innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)₂] in the field of emerging infectious diseases, as well as for certain drug intoxications.

Wallix is a software company providing cyber security solutions, WALLIX Group is a European specialist in privileged account governance. In response to recent regulatory change (NIS/GDPR in Europe and OVIs in France) and the cyber security threats affecting all companies today, Bastion helps users protect their critical IT assets: data, servers, terminals and connected objects. It is the first market solution to have been awarded first-level security certification (CSPN) by France’s National Cybersecurity Agency (ANSSI) and thus meet all of the criteria for regulatory compliance. WALLIX accompanies more than 770 companies and organizations on a day-to-day basis. Its solutions are marketed through a network of more than 160 resellers and trained and accredited integrators. Listed on Euronext under the code ALLIX, WALLIX Group is a leader on the PAM market with a strong presence throughout Europe and EMEA. Alain Afflelou, Dassault Aviation, Gulf Air, Maroc Telecom, McDonald’s, Michelin, and PSA Peugeot-Citroën trust WALLIX to secure their information systems.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

eXo Platform (https://www.exoplatform.com) is an open source social collaboration platform that is highly extensible and based on open standards. With eXo you can not only build an enterprise social network, but you can also build a website, a social intranet or a community website. Hundreds of large organizations—in sectors ranging from government and financial services to telecom—use eXo products today, as do thousands of enterprises in other sectors through the company’s strategic partnership with Red Hat. eXo operates globally and has offices in the United States, France, Tunisia, Ukraine and Vietnam.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Nosopharm SAS is a biotechnology company focused on the research and development of antibacterial molecules to combat multidrug-resistant gram-negative pathogens. Established in 2009 and headquartered in Nimes, France, the company specializes in Odilorhabdins, a novel class of antibiotics designed to address critical hospital-acquired infections caused by bacteria such as Escherichia coli and Pseudomonas aeruginosa. Notable products include NOSO-95179, which targets Carbapenem-resistant Enterobacteriaceae, and NOSO-95400, aimed at broader multidrug-resistant gram-negative infections. Nosopharm employs an innovative drug discovery platform that utilizes the medicinal properties of microbial biodiversity, particularly from the bacterial genera Xenorhabdus and Photorhabdus, allowing for the effective screening and characterization of bioactive compounds. The company is dedicated to addressing the pressing medical need for effective treatments against antibiotic-resistant infections.

Implanet provide Gold Standard implants of uncompromising and indisputable quality to the various surgical markets. It is destined for healthcare professionals treating orthopedic patients. Implanet isa company that provides modern solutions (services, along with Gold Standard products) that allow healthcare professionals to improve their productivity while contributing to society's urgent need to reduce healthcare costs. They believe that today, companies can evolve in the context of globalization while being socially and economically responsible. This organisation and business model provide an unprecedented level of security and information to the healthcare community.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Miliboo is a furniture brand that designs a range of contemporary furniture. The company’s product portfolio includes bar stools, sofas, tables, chairs, office chairs, garden furniture, and more. Miliboo was founded in 2007 and is based in Pringy, France.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet, electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios. The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Codenvy offers a cloud development platform that facilitates coding, building, and testing applications. By moving the local desktop workspace—comprising the editor, builder, and tester runtimes—into the cloud, Codenvy allows enterprises to access on-demand workspaces that promote collaboration and eliminate physical constraints. This innovative approach enhances the development process by providing a flexible and efficient environment tailored for modern software development needs.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Wallix is a software company providing cyber security solutions, WALLIX Group is a European specialist in privileged account governance. In response to recent regulatory change (NIS/GDPR in Europe and OVIs in France) and the cyber security threats affecting all companies today, Bastion helps users protect their critical IT assets: data, servers, terminals and connected objects. It is the first market solution to have been awarded first-level security certification (CSPN) by France’s National Cybersecurity Agency (ANSSI) and thus meet all of the criteria for regulatory compliance. WALLIX accompanies more than 770 companies and organizations on a day-to-day basis. Its solutions are marketed through a network of more than 160 resellers and trained and accredited integrators. Listed on Euronext under the code ALLIX, WALLIX Group is a leader on the PAM market with a strong presence throughout Europe and EMEA. Alain Afflelou, Dassault Aviation, Gulf Air, Maroc Telecom, McDonald’s, Michelin, and PSA Peugeot-Citroën trust WALLIX to secure their information systems.

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Eptica provides conversational and collaborative solutions powered by AI, transforming digital relationships between brands and individuals into meaningful conversations, and improving daily life for everyone. Their solutions include multi-channel communications, self-service, chat, email, knowledge base, and vecko. They offer linguistics consulting, professional services, customer support, and training.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Neolane, Inc. is a provider of conversational marketing technology that specializes in marketing automation and cross-channel campaign management software for both business-to-business and business-to-consumer marketers. The company enables organizations to create and maintain one-to-one lifetime dialogues with their customers, enhancing revenue generation and marketing efficiency. Neolane has demonstrated significant growth, recording $58 million in revenue in 2012, which represented a 40% increase from the previous year. The company has received recognition for its innovative approach, being named #64 on Forbes' list of America's Most Promising Companies in 2013. Neolane's technology is utilized by over 400 leading global companies, including Alcatel Lucent, Barnes & Noble, Orange, Sears Canada, Sephora Europe, and Sony Music, helping them navigate customer engagement challenges effectively.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Implanet provide Gold Standard implants of uncompromising and indisputable quality to the various surgical markets. It is destined for healthcare professionals treating orthopedic patients. Implanet isa company that provides modern solutions (services, along with Gold Standard products) that allow healthcare professionals to improve their productivity while contributing to society's urgent need to reduce healthcare costs. They believe that today, companies can evolve in the context of globalization while being socially and economically responsible. This organisation and business model provide an unprecedented level of security and information to the healthcare community.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

GliSODin Skin Nutrients is a professional medical line of nutricosmetics focused on optimal internal support. It provides the skin with essential nutrients and functions to protect it from the effects of oxidative stress. GliSODin Skin Nutrients was founded in 2008 and is based in Paris, France.

Founded in 2001, Availpro is a leading provider of e-booking software solutions which allows hotels to increase their occupancy and revenue while saving costs. Availpro provides innovative and critical tools to help managers operate their on-line distribution, maximise commission-free bookings from their official website and facilitate decision-making processes regarding price optimisation. Availpro is a versatile, international team of 75 people. The main concept behind Availpro is to provide you, as a hotel owner, with a fully integrated online distribution solution capable of managing every aspect of the process, from hotel management to distribution channels. Availpro has developed unrivalled expertise in this field, designing and deploying connectivities and gateways between a variety of different software solutions and platforms. Availpro partners with more than 300 compagnies around the world including largest OTA’s, meta-search portals, Global Distribution Systems (GDS) and PMS & CRS providers. This work is guided by a clear ambition: to make the distribution process ultra-simple and time-efficient, and to limit complexity wherever possible. These high-tech, two-way connectivities work around the clock, which makes Availpro an ultra-reliable, high-performance and profitable online distribution tool.

Cellnovo Group SA is a medical technology company based in Paris, France, that focuses on developing and marketing innovative mobile diabetes management systems. Its flagship product includes a cordless micro-pump for insulin administration, an integrated activity monitor, and a cellular-enabled wireless touchscreen handset that connects securely to servers for real-time data access. This system allows users to manage insulin injections effectively while enabling family members and healthcare professionals to monitor the patient's condition remotely. The company aims to empower individuals with diabetes by providing tools that simplify management and enhance their quality of life. Cellnovo markets its products through a direct sales force in the United Kingdom and France, as well as through international distributors. Additionally, it has partnered with Diabeloop SA to develop an artificial pancreas solution, further expanding its commitment to innovative diabetes care. The company was incorporated in 2014 and seeks to transform diabetes management through thoughtful design and modern technology.

Miliboo is a furniture brand that designs a range of contemporary furniture. The company’s product portfolio includes bar stools, sofas, tables, chairs, office chairs, garden furniture, and more. Miliboo was founded in 2007 and is based in Pringy, France.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

EVE offers massively multiplayer online roleplaying games. The company’s portfolio includes Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

eXo Platform (https://www.exoplatform.com) is an open source social collaboration platform that is highly extensible and based on open standards. With eXo you can not only build an enterprise social network, but you can also build a website, a social intranet or a community website. Hundreds of large organizations—in sectors ranging from government and financial services to telecom—use eXo products today, as do thousands of enterprises in other sectors through the company’s strategic partnership with Red Hat. eXo operates globally and has offices in the United States, France, Tunisia, Ukraine and Vietnam.

IDbyME is a fashion and clothing company offering fully customizable items under the MoodbyMe brand.

Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches. The company is headquartered in Reinach, Switzerland.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches. The company is headquartered in Reinach, Switzerland.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Bonitasoft fully supports digital operations and IT modernization with Bonita, an open-source and extensible platform for automation and optimization of business processes. The Bonita platform accelerates development and production with clear separation between capabilities for visual programming and for coding. Bonita integrates with existing information systems, orchestrates heterogeneous systems, and provides deep visibility into processes across the organization.

Convertigo S.A. is a French company that specializes in enterprise mashups and mobile application development. Founded in 1994 and formerly known as Twinsoft, Convertigo provides the Convertigo Enterprise Mashup Server (C-EMS), which allows organizations to utilize existing assets for creating new web applications. The C-EMS includes various components, such as the Mashup Composer for building custom applications, the Web Integrator for migrating legacy systems to service-oriented architecture, and tools for clipping and modernizing older applications. Additionally, Convertigo offers a Mobile Application Development Platform (MADP) that supports both cloud-based and on-premise solutions, designed to facilitate the rapid development of mobile applications by connecting enterprise data through a wide range of connectors. With over 50,000 installations of its community edition, Convertigo has established a strong presence in the mobility market, serving notable clients in finance and retail sectors. The company is recognized for its innovative technologies and commitment to meeting the evolving needs of its customers.

Implanet provide Gold Standard implants of uncompromising and indisputable quality to the various surgical markets. It is destined for healthcare professionals treating orthopedic patients. Implanet isa company that provides modern solutions (services, along with Gold Standard products) that allow healthcare professionals to improve their productivity while contributing to society's urgent need to reduce healthcare costs. They believe that today, companies can evolve in the context of globalization while being socially and economically responsible. This organisation and business model provide an unprecedented level of security and information to the healthcare community.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Bag Tech specializes in the development, design, and manufacturing of a diverse range of bags and backpacks. The company produces practical and durable products at wholesale prices, utilizing a facility in Sialkot, Pakistan, which spans over 10,000 square feet. Skilled craftsmen employ modern technology to ensure meticulous care in the manufacturing process. Bag Tech's product lineup includes various types of bags such as kit bags, travel kits, sports kits (including cricket, hockey, boxing, and karate), gym bags, school bags, backpacks, and specialized bags for helmets, shoes, and laptops. Additionally, the company offers protective covers for sports equipment and a selection of ladies' bags, catering to a wide array of customer needs.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Ekinops is a provider of next-generation optical transport solutions for service providers and private networks. Its carrier-grade solutions leverage expertise in 10G transmission, aggregation and Forward Error Correction (FEC) to allow operators to cost-effectively increase data transport capacity over dark fiber, CWDM, DWDM, SONET/SDH, IP and SAN networks.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Median Technologies SA specializes in the development and marketing of software products and platforms for medical image analysis, primarily focusing on oncology. Founded in 2002 and headquartered in Valbonne, France, the company operates internationally, offering solutions that enhance the diagnosis and treatment of cancer patients. Its key products include iBiopsy, an imaging platform that utilizes AI for biomarker identification, and iSee, which supports image analysis and management in clinical trials. Additionally, Median provides a range of imaging contract research services, including study startup, data management, and scientific consulting to optimize clinical trials. The company collaborates with a contract research organization and Canon to enhance its imaging technologies and services, aiming to improve patient care and streamline drug development processes.

Implanet provide Gold Standard implants of uncompromising and indisputable quality to the various surgical markets. It is destined for healthcare professionals treating orthopedic patients. Implanet isa company that provides modern solutions (services, along with Gold Standard products) that allow healthcare professionals to improve their productivity while contributing to society's urgent need to reduce healthcare costs. They believe that today, companies can evolve in the context of globalization while being socially and economically responsible. This organisation and business model provide an unprecedented level of security and information to the healthcare community.

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

aveni delivers innovative metallization processes that improve device performance and yield, enabling future technologies, today. Their production-ready solutions revolutionize the copper-plating process for damascene and TSV applications critical to semiconductor and MEMS device manufacturing. aveni’s Electrografting (eG™) technology is a wet, electrochemical-based process that enables the growth of extremely high-quality thin films of various types. Chemicalgrafting (cG™) is based on the same fundamental mechanisms as Electrografting, but is used on nonconductive substrates. Both technologies have been successfully demonstrated in manufacturing at and below the 14 nm node, as well as 40:1 aspect ratios. The company was originally founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA) to develop and market groundbreaking nanometric deposition technologies for a variety of electronic applications. Since that time, aveni has partnered with several R&D centers, and leading global equipment and device manufacturers on a variety of projects. Based in Massy, France, the company has a strong team of scientists and engineers who excel in the fields of surface science, chemistry, electrochemistry, physics, materials science and semiconductors.

Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

Streamcore is a leading provider of visibility and dynamic performance control solutions for managing interactive applications and real-time communications (VoIP, video…) delivery over the WAN. Streamcore products enable enterprises to benefit from all-in-one visibility - network, applications, VoIP, video -, real-time monitoring and advanced on-demand reporting from a single centralized management console. What makes Streamcore solutions unique is that visibility and advanced performance control are tied together and can be enabled from data centers to ensure fast deployment and cost-efficiency.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps IT teams meet the needs of the modern digital workplace.